DA Davidson cuts Salesforce stock price target on growth concerns By Investing.com

DA Davidson cut Salesforce’s price target to $175 from $200 while keeping a Neutral rating, citing no clear support for a more constructive outlook despite solid Agentforce traction. Salesforce’s Q1 fiscal 2027 results beat expectations with EPS of $3.88 vs. $3.13 consensus and revenue of $11.13 billion vs. $11.06 billion, but guidance only implies 7% to 8% constant-currency organic revenue growth. Other brokers remain positive, with price targets ranging from $250 to $315, leaving the stock and outlook mixed.

Analysis

The market is telling us CRM is no longer trading like a “show me” growth compounder; it’s trading like a durable cash-flow software platform with a capped multiple until product monetization proves itself. The key second-order effect is that Agentic AI spend is becoming a valuation battleground: if Salesforce can turn Agentforce/Data Cloud into sustained ACV expansion, it can re-rate back toward premium cloud names, but if not, the segment risks becoming a large R&D sink that supports sentiment without meaningfully lifting revenue per customer.

The downgrade matters less for the stock itself than for the broader software tape. When a bellwether with AI exposure gets its multiple compressed while execution is still acceptable, it raises the bar for adjacent “AI application” names that are priced on future attach rates rather than current monetization. In practice, that can pressure high-multiple SaaS peers with similar narratives but weaker current-year growth acceleration, especially those that already rely on second-half reacceleration stories.

The contrarian view is that consensus may be underestimating the power of margin stability here. If growth stays in the high-single digits and operating margin holds, CRM’s free-cash-flow profile can still justify a higher floor than the current sell-side tone implies. The market is likely overreacting to the absence of near-term acceleration while underpricing the possibility that AI becomes a gradual mix tailwind rather than an immediate revenue step-function.

Catalyst timing is important: near term, this is a multiple story over the next 2-6 weeks; over 2-3 quarters it becomes a proof-point story around renewal quality and AI attach. The biggest downside risk is not a revenue miss but another quarter of “good but not enough,” which would keep the multiple compressed even if fundamentals remain stable. Upside would require evidence that AI products are driving net-new wallet share, not just seat expansion within the installed base.

Key Decisions for Investors

• Stay market-neutral on CRM for 4-8 weeks; avoid outright longs until there is evidence of reacceleration, since the stock is likely to trade on multiple compression/expansion rather than fundamentals in the near term.
• If long CRM is required, use a call spread instead of stock: buy 6-9 month calls and finance with a higher strike sale to express upside from AI monetization while limiting downside if growth remains merely stable.
• Pair trade: long a profitable AI infrastructure name or a more demonstrably monetizing software compounder versus short CRM over 1-2 quarters; the relative trade benefits from capital rotating away from “AI story” SaaS into names with clearer revenue conversion.
• For investors already overweight large-cap software, trim exposure into strength and rotate toward names with cleaner second-derivative growth, as CRM’s muted guidance makes it a lower-conviction multiple anchor in the sector.
• Set a tactical add point only if CRM reclaims prior support on volume after an earnings/guidance reset; otherwise, the risk/reward remains skewed to dead money for the next reporting cycle.